POSTPONED: Primary Care Symposium Focusing on Nephrology and Oncology

NOTICE:  The Primary Care Symposium Focusing on Nephrology and Oncology scheduled for Saturday, November 3, 2018, has been postponed until the spring of 2019.


CME Course for Primary Care Practitioners 
4.5 AMA PRA CME Category 1 Credits

The symposium is designed to provide practitioners with the knowledge they need to identify and treat patients diagnosed with kidney disease or cancer.


8:00 a.m. Registration & Continental Breakfast

8:30 a.m. Welcome & Announcements

Alexander Liang, M.D., and R. Steven Paulson, M.D.

8:45 a.m. Introduction to CAR T-Cell Therapy

Houston Holmes, M.D.

9:30 a.m. GFR/eGFR: Filtering Out the Confusion

Michael R. Wiederkehr, M.D., F.A.C.P., F.A.S.N.

10:15 a.m. Morning Break

10:30 a.m. Clinical Rationale for Proton Therapy

Jared Sturgeon, M.D., Ph.D.

11:15 a.m. Resistant Hypertension

Cindy L. Corpier, M.D.

12:00 p.m. Lunch

12:30 p.m. Updates in Gynecologic Oncology 2018

Reagan M. Street, M.D., MMS

1:15 p.m. Nephrotoxicity of Herbal Medicines, Heavy Metals, and NSAIDS

Daniel S. Richey, D.O.

2:00 p.m. Closing Remarks

TARGET AUDIENCE: This conference is targeted for Practitioners specializing in Family Practice, Internal Medicine, and Obstetrics-Gynecology.

PURPOSE AND CONTENT: This conference is designed to offer attendees updates on kidney disease and cancer, its management, and treatment options that can be utilized in everyday practice to help patients to make choices and improve patient outcomes.

EDUCATIONAL OBJECTIVES: At the conclusion of this conference, participants will be able to:
• Identify the stages and management of chronic kidney disease (CKD)
• Understand the current management therapies in resistant hypertension
• Define and characterize the use of nephrotoxic drugs and their effect on the kidneys
• Identify immunotherapy treatment options utilizing a patient’s own blood cells to fight cancer
• Understand the uses of proton therapy to eliminate cancer cells
• Review the current diagnoses and treatment options of cancers related to a woman’s reproductive organs

DISCLOSURE OF FACULTY AND PROVIDER RELATIONSHIPS: All faculty and planning committee members participating in this course are required to disclose to participants any relationship, including financial interest or affiliation with a commercial company. Full disclosure of faculty and planning committee relationships will be made available to participants in conference materials.

FACULTY: Alexander Liang, M.D., R. Steven Paulson, M.D., Houston Holmes, M.D., Michael R. Wiederkehr, M.D., Jared Sturgeon, M.D., Ph.D., Cindy L. Corpier, M.D., Reagan M. Street, M.D., MMS, and Daniel S. Richey, D.O.

PLANNING COMMITTEE: Ed Bryson, Laura Sturdivant, Mollyn Shew, Sandra Simpson, Breck Yakulis, and Alison Zvolanek.

DESIGNATION STATEMENT: The Texas Medical Association designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Texas Medical Association, Dallas Nephrology Associates and Texas Oncology. The Texas Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

REGISTRATION FEES: $25 per registrant (includes meals and conference materials)

ONLINE REGISTRATION: Register via credit card.

REGISTRATION INFORMATION: The seminar is open to physicians and other health professionals. Advance registration and payment are required in order to confirm your reservation. Registration is limited to seating capacity. Registration ends on November 2, 2018, at 5 p.m. Walk-in registrants will be accepted based on seating availability and payment can be made by checks payable to Dallas Nephrology Associates, 1420 Viceroy Drive, Dallas, TX 75235. There will be no refunds allowed after October 28, 2018.


For the convenience of those attending, lunch and breaks are provided at no additional cost.  As the temperature in the room may vary, it is advisable to bring a jacket to ensure your comfort during the sessions.  For additional information or questions, please send email to or call 214.579.6810.



About Dallas Nephrology Associates

For over 45 years, Dallas Nephrology Associates (DNA) has been caring for patients with kidney disease, hypertension, transplants, and complicated electrolyte disorders.  While much has changed over the years, one thing remains constant, DNA’s pledge to provide our patients with expert personalized care, using the most advanced treatments and state-of-the-art technologies. Equally important is our excellent team of providers and support staff who care for our patients with compassion and dedication.  DNA has over 85 specialized physicians and over 25 conveniently located offices across the Dallas Fort Worth metroplex.  For a complete list of our physicians and providers, visit

About Texas Oncology

For more than 30 years Texas Oncology has provided treatment and hope to people throughout the state. As a pioneer of community-based cancer treatment, we have a presence in just about every corner of Texas — including yours. With more than 175 sites of service and 420 physicians across the state, we can help you in the fight of your life. The practice delivers high-quality, high-touch care to help cancer patients achieve “More breakthroughs. More victories.”® in their fight against cancer. Texas Oncology is an independent, physician-led practice delivering leading-edge technology and treatment options and conducting innovative research. Founders of the practice pioneered community-based care to enable more cancer patients to receive high-quality care while staying close to the critical support of family and friends.